EGFR and lung adenocarcinoma: Further phase III trials, which compared the outcomes of first- or second-line EGFR-TKI treatments with those of platinum doublets, confirmed the beneficial effects of mEGFRs on the progression-free survival and response rates in patients with lung adenocarcinoma [7].